SMILES string
N1([C@@H]([C@H]([C@@H]([C@H](C1)O)O)O)CO)CCO
InChI key
IBAQFPQHRJAVAV-ULAWRXDQSA-N
InChI
1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
biological source
synthetic (organic)
assay
≥98% (HPLC)
form
powder
mp
142-147 °C
solubility
water: 5 mg/mL, clear, colorless to faintly yellow
storage temp.
room temp
Quality Level
1 of 4
本產品 | B6032 | B7535 | 14879 |
|---|---|---|---|
| biological source synthetic (organic) | biological source - | biological source - | biological source - |
| assay ≥98% (HPLC) | assay ≥99.0% (titration) | assay ≥98.0% (titration) | assay ≥99.0% (NT) |
| Quality Level 200 | Quality Level 200 | Quality Level 400 | Quality Level 200 |
| form powder | form crystalline powder | form powder | form powder |
| storage temp. room temp | storage temp. room temp | storage temp. - | storage temp. - |
| solubility water: 5 mg/mL, clear, colorless to faintly yellow | solubility water: 0.5 g/mL, clear, colorless to very faintly yellow | solubility H2O: 1 M, clear, colorless | solubility H2O: 1 M at 20 °C, clear, colorless |
General description
Miglitol is an alpha-glucosidase inhibitor used as a glucose-lowering drug in diabetes research.[1]
存儲類別/等級
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Kyra Jones et al.
Bioorganic & medicinal chemistry, 19(13), 3929-3934 (2011-06-15)
Inhibition of intestinal α-glucosidases and pancreatic α-amylases is an approach to controlling blood glucose and serum insulin levels in individuals with Type II diabetes. The two human intestinal glucosidases are maltase-glucoamylase and sucrase-isomaltase. Each incorporates two family 31 glycoside hydrolases
Takuo Emoto et al.
The American journal of cardiology, 109(1), 42-46 (2011-09-29)
Repeated postprandial hyperglycemia may play an important role in the development of atherosclerosis by suppressing vascular endothelial function. Although miglitol suppresses the elevation of blood glucose levels shortly after a meal more than other α-glucosidase inhibitors, the effect of 3-month
Kenichi Matsuura et al.
Diabetes technology & therapeutics, 14(5), 423-429 (2012-02-10)
We compared the effects of miglitol as an add-on to bolus insulin and dose-intensified bolus insulin on postprandial glycemic excursions by continuous glucose monitoring (CGM). The glucose levels of 21 type 2 diabetes patients admitted for glycemic control were monitored
Kazutaka Aoki et al.
Acta diabetologica, 49(3), 225-230 (2011-09-08)
We recently reported that the administration of miglitol alone just before breakfast improved postprandial hyperglycemia and increased active glucagon-like peptide-1 (GLP-1) levels after lunch in men without diabetes. Miglitol and dipeptidyl peptidase-4 inhibitors, such as sitagliptin, enhance plasma active GLP-1
Kazuki Mochizuki et al.
Bioscience, biotechnology, and biochemistry, 74(12), 2470-2474 (2010-12-15)
β(2) integrins (CD11s/CD18) promote the attachment of leukocytes to vascular endothelial cells. We performed in this study sucrose loading to rats with moderate postprandial hyperglycemia with/without once-daily dosing of the α-glucosidase inhibitor, miglitol, for 4 days under 4-h fasting conditions.
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務